Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Drops By 24.9%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBGet Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 65,500 shares, a drop of 24.9% from the January 15th total of 87,200 shares. Based on an average daily trading volume, of 28,700 shares, the short-interest ratio is currently 2.3 days. Currently, 0.3% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

Read Our Latest Analysis on Anebulo Pharmaceuticals

Insider Buying and Selling at Anebulo Pharmaceuticals

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the completion of the acquisition, the director now directly owns 15,467,300 shares in the company, valued at approximately $15,312,627. The trade was a 188.23 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 85.90% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. King Luther Capital Management Corp acquired a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 59,662 shares of the company’s stock, valued at approximately $100,000. King Luther Capital Management Corp owned about 0.23% of Anebulo Pharmaceuticals at the end of the most recent quarter. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Stock Performance

NASDAQ ANEB opened at $1.33 on Friday. The company has a market capitalization of $34.49 million, a PE ratio of -4.43 and a beta of -1.15. Anebulo Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $3.30. The company has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.74.

About Anebulo Pharmaceuticals

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Read More

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.